Faculty of Life Sciences and Medicine, King's College London, London, UK.
Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Neurourol Urodyn. 2023 Apr;42(4):822-836. doi: 10.1002/nau.25167. Epub 2023 Mar 6.
Sacral neuromodulation (SNM) is a treatment approved for use in several conditions including refractory overactive bladder (OAB) and voiding dysfunction. Chronic pelvic pain (CPP) is a debilitating condition for which treatment is often challenging. SNM shows promising effect in patients with refractory CPP. However, there is a lack of clear evidence, especially in long-term outcomes. This systematic review will assess outcomes of SNM for treating CPP.
A systematic search of MEDLINE, Embase, Cochrane Central and clinical trial databases was completed from database inception until January 14, 2022. Studies using original data investigating SNM in an adult population with CPP which recorded pre and posttreatment pain scores were selected. Primary outcome was numerical change in pain score. Secondary outcomes were quality of life assessment and change in medication use and all-time complications of SNM. Risk of bias was assessed using the Newcastle Ottawa Tool for cohort studies.
Twenty-six of 1026 identified articles were selected evaluating 853 patients with CPP. The implantation rate after test-phase success was 64.3%. Significant improvement of pain scores was reported in 13 studies; three studies reported no significant change. WMD in pain scores on a 10-point scale was -4.64 (95% confidence interval [CI] = -5.32 to -3.95, p < 0.00001) across 20 studies which were quantitatively synthesized: effects were maintained at long-term follow-up. Mean follow-up was 42.5 months (0-59). Quality of life was measured by RAND SF-36 and EQ-5D questionnaires and all studies reported improvement in quality of life. One hundred and eighty-nine complications were reported in 1555 patients (Clavien-Dindo Grade I-IIIb). Risk of bias ranged from low to high risk. Studies were case series and bias stemmed from selection bias and loss to follow-up.
Sacral Neuromodulation is a reasonably effective treatment of Chronic Pelvic Pain and significantly reduces pain and increases patients' quality of life with immediate to long-term effects.
骶神经调节(SNM)是一种已批准用于多种疾病的治疗方法,包括难治性膀胱过度活动症(OAB)和排尿功能障碍。慢性盆腔疼痛(CPP)是一种使人衰弱的疾病,其治疗通常具有挑战性。SNM 对难治性 CPP 患者显示出有希望的效果。然而,缺乏明确的证据,特别是在长期结果方面。本系统评价将评估 SNM 治疗 CPP 的结果。
从数据库创建到 2022 年 1 月 14 日,对 MEDLINE、Embase、Cochrane 中心和临床试验数据库进行了系统搜索。选择了使用原始数据调查在 CPP 成年人群中使用 SNM 的研究,这些研究记录了治疗前后的疼痛评分。主要结果是疼痛评分的数值变化。次要结果是生活质量评估以及药物使用和 SNM 的所有时间并发症的变化。使用纽卡斯尔-渥太华工具评估队列研究的偏倚风险。
在 1026 篇确定的文章中,有 26 篇评估了 853 例 CPP 患者。测试阶段成功后的植入率为 64.3%。13 项研究报告疼痛评分显著改善,3 项研究报告无显著变化。20 项研究中,疼痛评分在 10 分制上的 WMD 为-4.64(95%置信区间[CI] = -5.32 至-3.95,p < 0.00001):这些研究进行了定量综合,结果表明效果在长期随访中得以维持。平均随访时间为 42.5 个月(0-59)。生活质量通过 RAND SF-36 和 EQ-5D 问卷进行测量,所有研究均报告生活质量有所改善。在 1555 名患者中报告了 189 种并发症(Clavien-Dindo 分级 I-IIIb)。偏倚风险从低到高。研究为病例系列研究,偏倚源于选择偏倚和随访丢失。
骶神经调节是慢性盆腔疼痛的一种合理有效的治疗方法,可显著减轻疼痛并提高患者的生活质量,具有即时和长期效果。